[Inspiring Target] IL-4R Alpha, a Potential Drug Target Worth over $10 Billion
Variant Boosters, Bivalent and Polyvalent Vaccines… Who’s Going to Break the Stalemate with COVID-19?
ACROBiosystems announces the release of their latest BA.2.75 antigen products
Newly launched——Useful Tools for Nucleic Acid Contamination Removal
ACROBiosystems are going full steam ahead on developing a collection of recombinant antigens for emergency SARS-CoV-2 variants. The reagents can be used to evaluate the efficacy of the antibodies and vaccination.
ACROBiosystems developed a series of GMP grade cytokines under the GMP grade quality management system. Those products are all suitable for T/NK cell generation, activation, and proliferation in cell therapy research.
This web search service is supported by Google Inc.